The estimated Net Worth of Scott Andrew Smith is at least $2.55 million dollars as of 3 March 2024. Mr Smith owns over 140,727 units of BioAtla stock worth over $156,228 and over the last 10 years he sold BCAB stock worth over $1,565,965. In addition, he makes $824,515 as Pres & Director at BioAtla.
Mr has made over 29 trades of the BioAtla stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 140,727 units of BCAB stock worth $251,901 on 3 March 2024.
The largest trade he's ever made was exercising 140,727 units of BioAtla stock on 3 March 2024 worth over $251,901. On average, Mr trades about 3,147 units every 32 days since 2014. As of 3 March 2024 he still owns at least 87,278 units of BioAtla stock.
You can see the complete history of Mr Smith stock trades at the bottom of the page.
Scott Andrew Smith is the Pres & Director at BioAtla.
As the Pres & Director of BioAtla, the total compensation of Mr Smith at BioAtla is $824,515. There are 1 executives at BioAtla getting paid more, with Dr. Jay M. Short having the highest compensation of $1,057,577.
Mr Smith is 59, he's been the Pres & Director of BioAtla since . There are 2 older and 4 younger executives at BioAtla. The oldest executive at BioAtla, Inc. is Richard A. Waldron, 67, who is the Chief Financial Officer.
Scott's mailing address filed with the SEC is C/O BIOATLA, INC. 11085 TORREYANA ROAD, , SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B... et Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BioAtla executives and other stock owners filed with the SEC include: